Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Blood (2023) 142 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2023-181628

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Blood (2022) 140 (Supplement 1): 9908–9910.

https://doi.org/10.1182/blood-2022-162186

Published: 2022

Journal Articles

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 9335–9337.

https://doi.org/10.1182/blood-2022-163180

Published: 2022

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz

Blood (2021) 138 (Supplement 1): 2459.

https://doi.org/10.1182/blood-2021-150200

Published: 2021

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Dolores Caballero, Ranjana Advani, Raquel de Oña, Ana Marin Niebla, María José Terol, Domingo Domenech Eva, Nawal Bendris, Julie Mackey Ahsan, Mollie Leoni, Francine M. Foss

Blood (2021) 138 (Supplement 1): 621.

https://doi.org/10.1182/blood-2021-147279

Published: 2021

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Blood (2021) 138 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2021-147685

Published: 2021

Journal Articles

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Beatriz Rey Búa, Ana Jiménez Ubieto, MDPhD, Jose Javier Sanchez Blanco, Pau Abrisqueta, MD PhD, Antonio Gutierrez, Angel Ramirez Payer, Eva Giné, MD PhD, Izaskun Cebeiro, Sr., Maria Jose Terol, Fatima De la Cruz, MD, Rafael Andreu, María José Ramírez Sánchez, Adolfo de la Fuente, Ma Cruz Viguria, Maria Jesús Peñarrubia, Carlos Grande, Dolores Caballero, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-140786

Published: 2020

Journal Articles

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-137025

Published: 2020

Journal Articles

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137020

Published: 2020

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Blood (2019) 134 (Supplement_1): 5333.

https://doi.org/10.1182/blood-2019-122900

Published: 2019

Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2018) 132 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2018-99-116277

Published: 2018

Journal Articles

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Blood (2018) 132 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2018-99-116868

Published: 2018

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

NARROW

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only